Skip to main content
Clinical Trials/JPRN-UMIN000047441
JPRN-UMIN000047441
Recruiting
未知

Real-world study on the efficacy of an adjunctive use of ipragliflozin for prevention of chronic kidney disease in patients with type 1 diabetes - Study on the efficacy of ipragliflozin for prevention of chronic kidney disease in type 1 diabetes

agasaki University0 sites360 target enrollmentJune 1, 2023
ConditionsType 1 diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type 1 diabetes
Sponsor
agasaki University
Enrollment
360
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2023
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
agasaki University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients with any of the following will be excluded: 1\)Patients administered any SGLT2 inhibitors except for ipragliflozin during 24 months after index date. 2\)Patients who administered ipragliflozin inadequately. 3\) Patients who had previous history of malignancy within 5 years before enrollment or 2 years before/after index date. 4\) Alcohol abuse or alcohol consumption \> 20g per day 5\) Patients who underwent hemodialysis within 5 years before enrollment or 2 years before/after index date. 6\) Patients who had a history of pregnancy and/or breastfeeding within 5 years before enrollment or 2 years before/after index date. 7\) Willingness not to provide informed consent. 8\) Judged inappropriate to participate by the study investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials